

FIG. 1b




FIG. 1a




FIG.1d




FIG.1c






FIG. 2d

FIG. 2e

FIG. 3

6/17




FIG. 4

7/17




FIG. 5





9/17

■ E:T RATIO 60  
 □ E:T RATIO 30  
 □ E:T RATIO 15  
 ▨ E:T RATIO 7.5

L1210 TARGETS (T)




FIG. 6B

10/17




FIG. 7

11/17




FIG. 8a





FIG. 8b








FIG. 10


## Insulin + hybridoma




## allo MLR Proliferation





## allo MLR IL-2






## allo MLR +/- anti B7













Proliferation of lymph node cells (Thymidine uptake)



Interleukin 2 secretion



Interferon gamma secretion

